Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389406 | 0.86 | DRD2 (0.45) | DRD2MALT1IDO1SIGMAR1AKT1 | |
| SCHEMBL24618345 | 0.83 | NQO2 (0.42) | DRD2MALT1CA12CA1CA2 | |
| SCHEMBL20945158 | 0.81 | ELANE (0.39) | MALT1ELANECA12CA1CA2 | |
| SCHEMBL20945232 | 0.81 | ELANE (0.45) | DRD2MALT1ELANE | |
| SCHEMBL15765305 | 0.80 | DRD2 (0.52) | DRD2MALT1IDO1SIGMAR1AKT1 | |
| SCHEMBL20945157 | 0.79 | PARP1 (0.47) | ELANE | |
| SCHEMBL3387585 | 0.79 | DRD2 (0.47) | DRD2MALT1SIGMAR1TDP1 | |
| SCHEMBL5116947 | 0.77 | ELANE (0.48) | ELANE | |
| SCHEMBL6302528 | 0.76 | ELANE (0.41) | ELANE | |
| SCHEMBL24618706 | 0.76 | DRD2 (0.43) | DRD2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | DRD2 4103/4885MALT1 4805/4885ELANE 2561/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | DRD2 4103/4885MALT1 4805/4885ELANE 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.